MediciNova Inc. reveals "encouraging interim data" from Lou Gehrig's trial
 

MediciNova Inc. reveals “encouraging interim data” from Lou Gehrig’s trial

MediciNova Inc. (NASDAQ:MNOV) reveals “encouraging interim data” from Lou Gehrig’s trial

MediciNova Presents Encouraging Interim Data
 

MediciNova Presents Encouraging Interim Data

MediciNova Presents Encouraging Interim Data - Hot Stock Herald

MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial o
 

MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland

MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland -

MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial o
 

MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland

MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland Nasdaq:MNOV

Outcomes data showed ALS patients who discontinued treatment with MediciNova's ibudil
 

Outcomes data showed ALS patients who discontinued treatment with MediciNova's ibudilast showed declines in muscle strength

Outcomes data showed ALS patients who discontinued treatment with MediciNova's ibudilast showed declines in muscle strength - MediciNova, Inc. (NASDAQ:MNOV) | Seeking Alpha